Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases.
about
Acceleration of epithelial cell syndecan-1 shedding by anthrax hemolytic virulence factors.Crystal structure of the Yersinia protein-tyrosine phosphatase YopH complexed with a specific small molecule inhibitorSuramin inhibits initiation of defense signaling by systemin, chitosan, and a beta-glucan elicitor in suspension-cultured Lycopersicon peruvianum cellsIdentification of novel drugs to target dormant micrometastasesSuramin blocks nucleotide triphosphate binding to ribosomal protein L3 from Trypanoplasma borreli.Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80/gp140/CUB domain-containing protein 1 in epithelia.Aurintricarboxylic acid blocks in vitro and in vivo activity of YopH, an essential virulent factor of Yersinia pestis, the agent of plague.Multiple regions of MAP kinase phosphatase 3 are involved in its recognition and activation by ERK2.Serendipitous discovery of light-induced (In Situ) formation of an Azo-bridged dimeric sulfonated naphthol as a potent PTP1B inhibitor.High-resolution dose-response screening using droplet-based microfluidics.Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assaysMolecular determinants of substrate recognition in hematopoietic protein-tyrosine phosphatase.Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases.Biomolecular Interactions of small-molecule inhibitors affecting the YopH protein tyrosine phosphatase.P2X(7) receptor antagonists display agonist-like effects on cell signaling proteins.Substrate selection influences molecular recognition in a screen for lymphoid tyrosine phosphatase inhibitorsActivation and regulation of purinergic P2X receptor channelsAnti-angiogenic therapies in cancer clinical trials.Targeting the PTPome in human disease.Differentiation induction of mouse embryonic stem cells into sinus node-like cells by suramin.Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1.Extracellular ATP drives systemic inflammation, tissue damage and mortality.Sorafenib-induced premalignant and malignant skin lesions.Cutaneous effects of BRAF inhibitor therapy: a case series.The quinic acid derivative KZ-41 prevents glucose-induced caspase-3 activation in retinal endothelial cells through an IGF-1 receptor dependent mechanism.Molecular Structure and Regulation of P2X Receptors With a Special Emphasis on the Role of P2X2 in the Auditory System.SHP-1: the next checkpoint target for cancer immunotherapy?Ca2+-dependent ATP release from A549 cells involves synergistic autocrine stimulation by coreleased uridine nucleotides.Suramin affects coupling of rhodopsin to transducin.The mechanism of heat shock activation of ERK mitogen-activated protein kinases in the interleukin 3-dependent ProB cell line BaF3.Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases.The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues.Characterization and Endocytic Internalization of Epith-2 Cell Surface Glycoprotein during the Epithelial-to-Mesenchymal Transition in Sea Urchin EmbryosTeratogenic effects of suramin on the chick embryo.Kinetics of inhibition of sperm beta-acrosin activity by suramin.Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors.Suramin is a novel activator of PP5 and biphasically modulates S100-activated PP5 activity.Characterization of [3H]-forskolin binding sites in young and adult rat brain cortex: identification of suramin as a competitive inhibitor of [3H]-forskolin binding.Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure.A high-throughput screening campaign to identify inhibitors of DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD).
P2860
Q25256591-73B2C3C4-A9B2-4788-AC1E-A32BBF57FB13Q27641444-610631B8-2F3B-4FD5-899F-DC90433BD21DQ28142406-777AC400-2408-4546-9BB8-0FB71C2F989DQ28394296-C7D3325C-5B84-4652-BC37-EA59969D9478Q30845458-CD1632BE-E81A-4246-B73F-A11E104041DEQ31037374-18DDEEC0-F55F-48B1-B10B-8429F637B23BQ31151176-674E5969-0F65-4C9B-B390-CCEDD8E17AAEQ31650853-FDF81053-42A6-436E-A9FC-AD3D7D98F09BQ33749872-2148BB62-8C3C-4DD3-9EAF-506807C90B30Q34112944-D284C96B-01DC-453A-8CCA-BCA00B314AE6Q34319607-D1566DAE-F841-4A7B-BADB-D760AA82A882Q34355962-8F204DF6-4646-4E83-BC3D-450A1561C850Q34504973-6CDE0C55-3262-4636-BF01-D2CFC010C9ABQ34513199-CEB2F838-38B5-418A-8B77-7E73B86CAC83Q34927539-5AE2051B-E7B5-4AFC-B618-F93F0F05FEFDQ34954874-3CD1E29F-F203-4ABC-92D2-E5129FDE9B35Q35122793-1250BE72-1BA8-40BA-8E12-A8CD45E554F8Q36181120-1623B010-C8A7-4C16-8FC3-2BA479E3622AQ36379394-2CEB4133-307F-4678-95A1-BB31C03AB224Q36572956-DA38268B-E778-4B8C-8DAF-FCD56EC1E1E5Q37263972-26ED0857-888C-4933-86EC-91C404114909Q37680164-858A3723-5444-438A-8CA9-D7B5FF49D533Q37854083-601D1F13-C0DA-4D68-B48B-F4E56B6241D1Q38049306-D84D6E82-60D2-44AC-816F-E24D6A6B5796Q38630428-263EC4B6-2008-492B-A713-F8078BC0B64EQ38655779-0A9E5417-A083-4DB5-985D-861400B96206Q38805738-33003116-5DE7-48B8-9AE1-4A39C687B3B9Q40093143-4E77F104-9555-429F-BE31-A7E2D246AADAQ40200930-E22E2D5E-6329-4BFC-9298-8E466EFA2483Q40852590-9875A1BE-2130-42CD-8700-69CCE70FD0C4Q41464016-F416D4F2-B88C-45DC-8264-E2E5304E2022Q42017071-D09D357C-863F-4379-85D4-F87CE5A5889BQ42031129-2B73EB7B-B6E7-4615-B6C3-2A99D132363BQ44319881-972DACAC-EA5A-419B-84A2-123879FBA103Q44462806-63CF5221-D3F6-4070-8CB4-CDC5863C320BQ44922742-277AD451-7B41-4FA9-A3EA-96C20D119406Q46227198-8022C08F-C0D7-48D5-A6A8-776BEA8AA445Q46643284-48B588DE-3BF1-4A5E-BB25-9104F36BA3E5Q46761334-3BA30CC6-5DC5-4FF4-BE06-EDD8BEBB7D66Q49590368-938B86FE-2012-4643-935F-8984FFAC0005
P2860
Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Suramin is an active site-dire ...... protein-tyrosine phosphatases.
@en
type
label
Suramin is an active site-dire ...... protein-tyrosine phosphatases.
@en
prefLabel
Suramin is an active site-dire ...... protein-tyrosine phosphatases.
@en
P2093
P2860
P356
P1476
Suramin is an active site-dire ...... protein-tyrosine phosphatases.
@en
P2093
P2860
P304
12281-12287
P356
10.1074/JBC.273.20.12281
P407
P577
1998-05-01T00:00:00Z